Is BioNTech SE (BNTX) a Buy, Sell, or Hold?
BioNTech SE
NASDAQ:BNTX
$90.4 USD
$0.33 (0.37%)
- Volume
- 923.47K
- Average Volume
- 958.47K
- Market Capitalization
- $22.86B
- P/E Ratio
- -15.41
- Dividend Yield
- 0.00%
- Price Target
- $135.00
- Year High
- $124.00
- Year Low
- $79.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ugur Sahin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BNTX |
| CUSIP | 09075V102 |
| CIK | 0001776985 |
| Web | https://www.biontech.de |
| Phone | 49 6131 9084 0 |
| Currency | USD |
| Employees | 7807 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.80 |
| Quick Ratio | 8.74 |
| Cash Ratio | 5.63 |
Sales & Book Value
| Annual Sales | $2.76B |
| Price / Sales | 7.03 |
| Cash Flow | 2.69 |
| Price / Cash Flow | 28.87 |
| Price / Book | 1.05 |
Price Target and Rating
| Average Stock Price Forecast | $135.00 |
| High Stock Price Forecast | $158.00 |
| Low Stock Price Forecast | $96.00 |
| Forecast Upside/Downside | -33.04% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 24 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.51 |
| Trailing P/E Ratio | -15.41 |
| PEG Ratio | 0.16 |
| P/E Growth | 0.16 |
| Net Income | $-1.09B |
| Net Margin | -44.67% |
| Pretax Margin | -41.88% |
| Return on Equity | -6.67% |
| Return on Assets | -5.93% |
Financials Score
| AltmanZ Score | 6.93 |
| Piotroski Score | 4.00 |
| Working Capital | 13.78B |
| Total Assets | 21.1B |
| Ebit | -1.17B |
| Market Cap | 19.99B |
| Total Liabilities | 2.38B |
Poll Results
About BioNTech SE (NASDAQ:BNTX) Stock
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Pha ... se 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock
2026-07-14 09:42:00
On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
2026-07-07 18:30:00
They may not remain cheap for too much longer.
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
2026-07-03 01:51:40
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper reported on Friday.
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
2026-06-17 02:38:57
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
2026-06-04 12:55:34
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
2026-06-01 11:01:12
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
2026-05-30 14:15:00
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
2026-05-22 05:00:00
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.
Frequently Asked Questions
-
What is the current BioNTech SE (BNTX) stock price?
-
BioNTech SE(NASDAQ:BNTX) stock price is $90.4 in the last trading session. During the trading session, BNTX stock reached the peak price of $124 while $79.52 was the lowest point it dropped to. The percentage change in BNTX stock occurred in the recent session was 0.37% while the dollar amount for the price change in BNTX stock was $0.33.
-
BNTX's industry and sector of operation?
-
The NASDAQ listed BNTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BNTX?
-
Sierk Pötting | MD, Chief Operating Officer & Member of Management Board
James Timothy Patrick Ryan | Chief Legal & Business Officer and Member of the Management Board
Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board
Ugur Sahin | Co-Founder, Chief Executive Officer & Chair of the Management Board
Jasmina Alatovic | Vice President Corporate Communications -
How many employees does BNTX have?
-
Number of BNTX employees currently stands at 7807. BNTX operates from An der Goldgrube 12, Mainz, RP 55131, DE.
-
Link for BNTX official website?
-
Official Website of BNTX is: https://www.biontech.de
-
How do I contact BNTX?
-
BNTX could be contacted at phone #49 6131 9084 0 and can also be accessed through its website. BNTX operates from An der Goldgrube 12, Mainz, RP 55131, DE.
-
How many shares of BNTX are traded daily?
-
The average number of BNTX shares traded daily for last 3 months was 958.47K.
-
What is the market cap of BNTX currently?
-
The market value of BNTX currently stands at $22.86B with its latest stock price at $90.4